Document is current
Any future updates will be listed below
-
Authors
Martin-Loeches, Ignacio
Shorr, Andrew F.
Wunderink, Richard G.
Kollef, Marin H.
Timsit, Jean-François
Yu, Brian
Huntington, Jennifer A.
Jensen, Erin
Bruno, Christopher J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02070757 at ClinicalTrials.govDocuments that mention this clinical trial
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
https://doi.org/10.1186/s13054-021-03773-5
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
https://doi.org/10.1186/s13054-021-03694-3
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
https://doi.org/10.1186/s13613-022-01084-8
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
Journal Title: Annals of Intensive Care
CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-022-01084-8
Content Type: article
Copyright: Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates 2023. Published by Elsevier Masson SAS
